Who is sponsoring NCT05107258?

NCT05107258 is sponsored by Pine Trees, Inc..

What drugs are being tested in NCT05107258?

Interventions in NCT05107258: The Pine Trees Health Test System.

What condition does NCT05107258 study?

NCT05107258 studies SARS (Severe Acute Respiratory Syndrome), Covid19.

Is NCT05107258 still recruiting?

NCT05107258 is currently completed. Last updated 4 November 2021.

Last reviewed 2021-11-04 · How we verify

NCT05107258

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care

Completed Last updated 4 November 2021

What this trial tests

trial testing The Pine Trees Health Test System in SARS (Severe Acute Respiratory Syndrome) in 195 participants. Completed in 16 September 2021.

Timeline

17 August 2021

Primary endpoint
16 September 2021

16 September 2021

Quick facts

Lead sponsor	Pine Trees, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	195
Start date	17 August 2021
Primary completion	16 September 2021
Estimated completion	16 September 2021
Sites	3 locations across United States

Drugs / interventions tested

The Pine Trees Health Test System

Conditions studied

SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →
Covid19 — all drugs for Covid19 →

Sponsor

Pine Trees, Inc.

Who can join

6 and older, any sex, with SARS (Severe Acute Respiratory Syndrome) or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The scope of this study is to validate the Pine Trees Health COVID-19 Molecular Test with unique clinical specimens from across two (2) geographically diverse point-of-care testing sites in the United States. The results will be analyzed and compared against results from the CDC 2019- Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. The primary objective is to generate clinical performance data for the Pine Trees Health COVID19 molecular diagnostic test in the point-of-care setting.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Current trends of clinical trials involving CRISPR/Cas systems.
Zhang S, Wang Y, Mao D, Wang Y, et al · · 2023 · cited 35× · PMID 38020120 · DOI 10.3389/fmed.2023.1292452
An Update on the Application of CRISPR Technology in Clinical Practice.
Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, et al · · 2024 · cited 33× · PMID 37269466 · DOI 10.1007/s12033-023-00724-z
Principles and Applications of CRISPR Toolkit in Virus Manipulation, Diagnosis, and Virus-Host Interactions.
Jamehdor S, Pajouhanfar S, Saba S, Uzan G, et al · · 2022 · cited 7× · PMID 35326449 · DOI 10.3390/cells11060999
Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.
de Morais CCPL, Correia EM, Bonamino MH, Vasconcelos ZFM. · · 2024 · cited 6× · PMID 39276086 · DOI 10.1089/hum.2024.020

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05107258 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pine Trees, Inc.
Last refreshed: 4 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05107258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing